HIV Prevention Takes Big Leap with USPSTF Recommendation for PrEP

November 21, 2018

National Policy Office – Washington, DC: 202-835-8373

Program and Administrative Office – Tampa, FL: 813-258-5929

For Immediate Release: 11.20.18


Media Contact:  Carl Schmid: (202) 669-8267


Rating Should Result in Expanded PrEP Access and Insurance Coverage

Washington, DC – Today, the United States Preventive Services Task Force (USPSTF) issued a strong endorsement of Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV. PrEP is a once daily medication that prevents the transmission of HIV. The proposed “A” grade recommendation for persons who are at risk of HIV solidifies PrEP as an effective HIV prevention tool and will help reduce new HIV infections in the United States.  There are currently about 40,000 new infections each year.
Once finalized, there should be no excuse for clinicians not to recommend PrEP to people who are at risk of HIV. Additionally, thanks to the Affordable Care Act, private insurers must cover PrEP without cost-sharing. As plan deductibles and patient cost-sharing have been rising, this recommendation will help affordability and access to PrEP. There are also coverage opportunities by Medicaid, along with Medicare after a separate coverage determination.
While the use of PrEP has been increasing and studies have demonstrated that it is bringing down the number of new HIV infections in certain areas, access in some communities and areas most impacted by HIV is still not occurring. With this USPSTF recommendation, The AIDS Institute trust clinicians will further educate themselves about PrEP and offer it to their patients at risk of HIV. With the USPSTF seal of approval, we expect to witness an expansion of PrEP, ultimately reducing the number of new HIV infections, and moving us closer to the end of AIDS in the United States.
Comments on the draft recommendation are due December 26, 2018.


The AIDS Institute is a national nonprofit organization that promotes action for social change through public policy, research, advocacy and education.

For more information and to become involved, visit or write to us at, and follow The AIDS Institute on Twitter @AIDSAdvocacy and Facebook at

Back to Resources